

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4269US1	SERIAL NO. 09/529,206
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		APPLICANT WANG ET AL.	
		FILING DATE June 13, 2000	GROUP ART UNIT 1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
DB	NAD	WO 94/03205	2/17/94	WIPO	—	—	
↓		WO 97/29195	8/4/97	WIPO	—	—	
DB		WO 98/14464	4/9/98	WIPO	—	—	
↓		WO 98 32855	6/30/98	WIPO	—	—	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

DB	NAD	Chen Y.-T., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94:1914 (1997).
↓		Jager, E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265 (1998).
		Parkhurst, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A0201 binding residues. J. Immunol. 157:2539 (1996).
		Wang, R., et al., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different from different open reading frames. J. Immunol. 161:3596 (1998).
DB	↓	Falk et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules Immunogenetics, Vol. 40: 238-241 (1994).

*Paul B. B.*

3/10/06



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2026-4269US1SERIAL NO.  
09/529,206

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

WANG ET AL.

FILING DATE  
June 13, 2000GROUP ART UNIT  
1643

Kawakami, Y et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating lymphocytes. J. Exp. Med., Vol. 180: 347 (1994).

Wang, R-F et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., Vol. 181, 799-804 (1995).

Rammensee, H.G. et al. MHC ligand and peptide motifs: first listing, Immunogenetics, Vol. 41: 178 (1995).

Wang, R-F, et al. Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Novel Human Cancer Antigen, J. Exp. Med. Vol. 183: 1131 (1996).

Wang and Rosenberg, Human tumor antigens recognized by T lymphocytes: implications for cancer therapy, J. Leukocyte Biology, Vol. 60: 296 (1996).

Wang, R-F et al., Identification of TRP-2 as a Human Tumor Antigen Recognized by cytotoxic T lymphocytes. J. Exp. Med., Vol. 184: 2203 (1996).

Kawakami Y et al. Identification of tumor-regression antigens in melanoma. 1. Important Advances in Oncology, 1996, eds. V. DeVita, S. Hellman, S.A. Rosenberg, Lippincott - Raven Publishers, Philadelphia, pp. 3-21

EXAMINER

N. G. G. G.

DATE CONSIDERED

9-15-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.